These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2031 related articles for article (PubMed ID: 18753864)

  • 21. Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection.
    Joseph O; Biodun O; Michael E
    J Coll Physicians Surg Pak; 2011 Jun; 21(6):356-9. PubMed ID: 21711992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
    Chaix ML; Ekouevi DK; Rouet F; Tonwe-Gold B; Viho I; Bequet L; Peytavin G; Toure H; Menan H; Leroy V; Dabis F; Rouzioux C;
    J Infect Dis; 2006 Feb; 193(4):482-7. PubMed ID: 16425126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
    Dao H; Mofenson LM; Ekpini R; Gilks CF; Barnhart M; Bolu O; Shaffer N
    Am J Obstet Gynecol; 2007 Sep; 197(3 Suppl):S42-55. PubMed ID: 17825650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa.
    Coetzee D; Hilderbrand K; Boulle A; Draper B; Abdullah F; Goemaere E
    Bull World Health Organ; 2005 Jul; 83(7):489-94. PubMed ID: 16175822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
    Kowalska A; Niemiec T; El Midaoui A; Burkacka E
    Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.
    Mofenson LM; Lambert JS; Stiehm ER; Bethel J; Meyer WA; Whitehouse J; Moye J; Reichelderfer P; Harris DR; Fowler MG; Mathieson BJ; Nemo GJ
    N Engl J Med; 1999 Aug; 341(6):385-93. PubMed ID: 10432323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
    Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to antiretrovirals in HIV-infected pregnant women.
    Weinberg A; Forster-Harwood J; McFarland EJ; Pappas J; Davies JK; Kinzie K; Barr EA; Paul SM; Salbenblatt CR; Soda E; Vazquez A; Levin MJ
    J Clin Virol; 2009 May; 45(1):39-42. PubMed ID: 19329355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
    Tempelman C; Timmermans S; Godfried MH; Dieleman JP; Boer K; van der Ende ME
    Ned Tijdschr Geneeskd; 2004 Oct; 148(41):2021-5. PubMed ID: 15553999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.
    Schulte J; Dominguez K; Sukalac T; Bohannon B; Fowler MG;
    Pediatrics; 2007 Apr; 119(4):e900-6. PubMed ID: 17353299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.
    Shapiro RL; Ndung'u T; Lockman S; Smeaton LM; Thior I; Wester C; Stevens L; Sebetso G; Gaseitsiwe S; Peter T; Essex M
    J Infect Dis; 2005 Sep; 192(5):713-9. PubMed ID: 16088820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short course zidovudine maternal treatment in HIV-1 vertical transmission: randomized controlled multicenter trial.
    Limpongsanurak S; Thaithumyanon P; Chaithongwongwatthana S; Thisyakorn U; Ruxrungtham K; Kongsin P; Tarounotai U; Chantheptaewan N; Triratwerapong T; Ubolyam S; Phanuphak P; Virutamasen P; Hanwanich M; Hawanon P; Chulasugondha P
    J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S338-45. PubMed ID: 11529355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV infection and zidovudine use in childbearing women.
    Sia J; Paul S; Martin RM; Cross H
    Pediatrics; 2004 Dec; 114(6):e707-12. PubMed ID: 15545619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical HIV transmission.
    Garcia-Tejedor A; Maiques V; Perales A; Lopez-Aldeguer J
    Acta Obstet Gynecol Scand; 2009; 88(8):882-7. PubMed ID: 19557554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.
    Carneiro M; Sanchéz A; Maneiro P; Angelosante W; Pérez C; Valleé M
    Placenta; 2001 Apr; 22 Suppl A():S13-8. PubMed ID: 11312622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Chaix ML; Tonwe-Gold B; Amani-Bosse C; Leroy V; Abrams EJ; Dabis F
    J Int AIDS Soc; 2010 Aug; 13():28. PubMed ID: 20678207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.
    Grosch-Woerner I; Puch K; Maier RF; Niehues T; Notheis G; Patel D; Casteleyn S; Feiterna-Sperling C; Groeger S; Zaknun D;
    HIV Med; 2008 Jan; 9(1):6-13. PubMed ID: 18199167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 102.